Philips account plan
Improving health through innovation
At a glance
Royal Philips is an Amsterdam-based health technology company with EUR 17,834 million of 2025 sales and about 65,000 employees.
Royal Philips (Koninklijke Philips N.V.) is a health technology company that sells imaging, interventional, monitoring and informatics platforms to hospitals and health systems, and grooming, oral care and mother-and-child products to consumers. It is headquartered in Amsterdam, present in 71 countries and employs about 65,000 people, with R&D centred on Eindhoven, Cambridge (US), Bengaluru and Beijing. In FY2025 sales were EUR 17,834 million (-1% nominal, +2% comparable), Adjusted EBITA EUR 2,195 million (12.3% margin) and net income EUR 897 million, after a loss of EUR (698) million in 2024. Health systems revenue mixes product sales, service fees, per-procedure fees, software licences and as-a-service contracts; Personal Health sells through retailers, online platforms and direct-to-consumer.
Business units
Diagnosis & Treatment
48% of 2025 group sales (EUR 8,531 million)Precision Diagnosis (MRI, ultrasound, CT, diagnostic X-ray) and Image Guided Therapy (Azurion interventional systems and devices), sold to hospitals directly and through distributors. Comparable sales were flat in 2025 and grew 2% in Q2 2026, with Image Guided Therapy growing high-single-digit for the 22nd consecutive quarter while Precision Diagnosis declined low-single-digit, weighed by China. Led by Bert van Meurs and Jie Xue.
Connected Care
28% of 2025 group sales (EUR 5,076 million)Monitoring (hospital patient monitoring, ambulatory monitoring), Enterprise Informatics (imaging and clinical informatics, cloud on AWS) and Sleep & Respiratory Care, for hospitals, ambulatory and home care providers. Comparable sales rose 3% in 2025; Enterprise Informatics is moving customers from on-premise to cloud and SaaS. Led by Julia Strandberg, with Shez Partovi heading Enterprise Informatics.
Personal Health
21% of 2025 group sales (EUR 3,673 million)Personal Care (shavers, OneBlade, Lumea IPL), Oral Healthcare (Sonicare) and Mother and Child Care (Philips Avent), sold through retailers, online platforms and the Philips online store. It grew 8% comparable in 2025 with an 18.0% Adjusted EBITA margin, and 8% again in Q2 2026. Led by Deeptha Khanna.
Other
3% of 2025 group sales (EUR 554 million)Innovation & Design, IP royalties and central costs. Sales fell from EUR 611 million in 2024, mainly on lower royalty income.
Strategic priorities
- Profitable growth plan 2026-2028
- Mid-single-digit comparable sales CAGR, a mid-teens Adjusted EBITA margin in 2028 and EUR 4.5-5.0 billion of cumulative free cash flow, set at the Capital Markets Day on February 10, 2026.
- Disproportionate focus on Monitoring and Interventional
- Segment-specific strategies replace the earlier 70-30 split; Image Guided Therapy targets mid-to-high-single-digit growth and an adjusted EBITA above 20% by 2028, and Connected Care a clear path to mid-teens margins.
- AI and platform innovation
- AI-powered platforms such as Azurion Eye, Verida spectral CT, helium-free 3.0T MRI and the ECG AI Marketplace, built on an installed base of more than 2.5 million systems, with partners AWS, Nvidia and Mayo Clinic.
- EUR 1.5 billion productivity programme
- Savings over 2026-2028 from cost competitiveness (CT platforms from seven to three), central functions cut 15% to 20% toward first-quartile benchmarks, and AI; EUR 258 million delivered year-to-date by Q2 2026.
- Patient safety and quality
- Respironics remains under the US consent decree, with no new sleep therapy or respiratory device sales in the US; an FDA warning letter followed inspections in September 2025. US sleep therapy re-entry is not included in the plan.
- Regional growth engines
- North America is the core growth engine, with large health systems seeking fewer, deeper partnerships; Europe posted double-digit order growth in Q2 2026; India, Indonesia and Saudi Arabia are named growth markets while China is handled selectively.
Latest results
In Q2 2026 Philips posted sales of EUR 4,360 million, +1% nominal and +4% comparable, with growth in all three segments. Adjusted EBITA was EUR 717 million, a 16.4% margin that includes a US tariff refund benefit; the underlying margin was 12.2%. Comparable order intake fell 1% as large North American Monitoring orders moved into Q3, after six consecutive quarters of growth, while the equipment order book stayed at a record level. First-half 2026 sales were EUR 8,265 million (+4% comparable). Philips reiterated 2026 comparable sales growth of 3%-4.5% and raised its Adjusted EBITA margin outlook to 13.5%-14.0% (including about 1% from the refund) and free cash flow to EUR 1.5-1.7 billion.
Investments and deals
- SpectraWAVE acquisition
- Coronary vascular imaging company acquired January 15, 2026; goodwill of EUR 169 million and contingent consideration of up to EUR 65 million tied to regulatory and revenue milestones.
- US manufacturing and R&D
- USD 150 million announced to expand US manufacturing and R&D, including ultrasound in Reedsville, Pennsylvania and Image Guided Therapy in Plymouth, Minnesota.
- Capital expenditure
- Net capital expenditures of EUR 660 million in 2025, in line with 2024; R&D held at around 9% of sales with fewer, bigger programmes.
- Divestments
- Emergency Care sold in 2025 (now Heartstream) among two divestments for EUR 77 million; the electronic medical records business was divested in Q2 2026, with a EUR 99 million gain.
Challenges and risks
- Tariffs and cost inflation
- Tariffs rose from about 1% to about 3% of cost of sales in 2025; e-components, freight and energy inflation cut the underlying Diagnosis & Treatment margin to 9.3% in Q2 2026.
- China
- Health systems sales in China are weak as centralised procurement expands; Precision Diagnosis declined low-single-digit partly because of China.
- Respironics legal and regulatory exposure
- Investigations by the SEC, DoJ, State Attorneys General and Australia's TGA continue, alongside securities claims and an Amsterdam Enterprise Chamber inquiry request.
- Slow informatics transition
- Enterprise Informatics sales declined mid-single-digit in Q2 2026 as customers move to cloud; orders take 12 to 18 months to turn into revenue.
- Order-to-sales conversion
- Larger deals and constrained installation capacity slow the conversion of orders into sales.
What leadership says
“Today marks the beginning of a next phase for Philips. We have stabilised the company, significantly improved our culture, our team and the fundamentals of our business.”
“In healthcare, AI is augmenting instead of replacing people”
“We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments”
“In 2025, we delivered on our commitments and drove performance every quarter”
Where a supplier can help
- Productivity and central-function savings
- The EUR 1.5 billion productivity programme and the 15% to 20% central-functions reduction open room for suppliers of automation, AI agents and process tooling that cut cost per transaction.
- Supply chain and tariff mitigation
- Tariff and e-component inflation, plus the regionalisation and dual-sourcing push, favour suppliers of components, logistics and sourcing analytics that help localise production.
- Cloud and AI informatics
- The move of Enterprise Informatics to cloud and SaaS and the AI platform agenda create demand for cloud, data, cybersecurity and AI regulatory-compliance partners.
- Installation and service capacity
- Constrained installation capacity slows order-to-sales conversion; field service, installation and project-management partners could help turn the record order book into revenue.
- Quality and regulatory compliance
- The Respironics consent decree and the FDA warning letter make quality management, regulatory documentation and audit tooling a standing need.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Philips?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Philips Annual Report 2025
- Royal Philips is a focused health technology company organised in three segments: Diagnosis & Treatment (48% of 2025 sales), Connected Care (28%) and Personal Health (21%), plus Other (3%: royalties, innovation, central costs); about 65,000 employees, headquartered in Amsterdam.
- FY2025 sales EUR 17,834 million, down 1% nominally (currency) but up 2% comparable; comparable order intake grew 6% (1% in 2024).
- Adjusted EBITA EUR 2,195 million, margin 12.3% (11.5% in 2024); income from operations EUR 1,424 million; net income EUR 897 million after a loss of EUR (698) million in 2024; free cash flow EUR 512 million, held down by EUR 1,025 million of Respironics settlement payments.
- Personal Health was the growth engine (+8% comparable, 18.0% Adjusted EBITA margin); Connected Care +3% (10.7%); Diagnosis & Treatment flat (11.7%), with Image Guided Therapy growing mid-single-digit and Precision Diagnosis declining low-single-digit.
- North America grew 3% comparable and Growth geographies 5%; China saw lower sales on adverse market conditions; tariffs rose from about 1% to about 3% of cost of sales.
- 2026 outlook: comparable sales growth 3%-4.5%, Adjusted EBITA margin 12.5%-13.0%, free cash flow EUR 1.3-1.5 billion. 2026-2028 targets: mid-single-digit comparable sales CAGR, mid-teens Adjusted EBITA margin in 2028, EUR 4.5-5.0 billion cumulative free cash flow, EUR 1.5 billion productivity savings.
- Strategic focus on platform innovation powered by AI (helium-free 3.0T MRI, Verida spectral CT, ECG AI Marketplace) and on its strongholds Image Guided Therapy, Monitoring, Ultrasound and Personal Health; SpectraWAVE (coronary imaging) acquired January 15, 2026; Emergency Care sold (now Heartstream); USD 150 million US manufacturing and R&D investment.
- Patient safety and quality remain the number one priority: Respironics still operates under the US consent decree (no new CPAP/BiPAP sales in the US) and an FDA warning letter in September 2025 followed inspections of nine facilities.
- Top risks: geopolitics, tariffs and US-China tensions, keeping pace with AI and health informatics, quality and regulatory compliance, supply chain resilience; dividend kept at EUR 0.85 per share.
- Philips Quarterly Report Q2 2026 (including semi-annual report 2026)
- Q2 2026 group sales EUR 4,360 million, +1% nominal and +4% comparable, with growth in all segments; comparable order intake fell 1% because certain large Connected Care orders shifted into Q3.
- Adjusted EBITA EUR 717 million, margin 16.4%, including a US tariff refund benefit of effectively 4.2 points; income from operations EUR 609 million including a EUR 186 million tariff refund benefit; net income EUR 386 million.
- Segments: Diagnosis & Treatment +2% comparable (Image Guided Therapy high-single-digit growth, Precision Diagnosis low-single-digit decline), Connected Care +2% (Monitoring mid-single-digit), Personal Health +8%.
- Growth geographies +13% comparable (Central Eastern Europe, Latin America, Indian subcontinent); Mature geographies +1%, North America +3%, Western Europe -2%.
- First half 2026: sales EUR 8,265 million, +4% comparable; Adjusted EBITA EUR 1,069 million, 12.9% including effectively 2.2 points of tariff refund.
- 2026 outlook: comparable sales growth 3%-4.5% reiterated; Adjusted EBITA margin raised to 13.5%-14.0% (including about 1% from the refund) and free cash flow to EUR 1.5-1.7 billion.
- Productivity savings of EUR 132 million in the quarter; on track for EUR 1.5 billion under the 2026-2028 programme.
- Innovations and deals: SmartIQ ultra-low-dose for Azurion, Titanion MR, 4D MR for radiation therapy; Poland modernisation of more than 200 hospitals; Region Stockholm hospital-at-home (up to 15,000 patients a year).
- Respironics investigations by the SEC, DoJ, State Attorneys General and Australia's TGA continue; an Amsterdam Enterprise Chamber decision on an inquiry into the recall is expected toward the end of Q3.
- Philips Q2 2026 results conference call transcript
- CEO Roy Jakobs and CFO Charlotte Hanneman present Q2 2026 (call held July 28, 2026, brought forward after the results were inadvertently published the evening before): comparable sales +4%, Adjusted EBITA margin 16.4% including the US tariff refund, 12.2% underlying.
- Order intake fell 1% after six consecutive quarters of growth as large North American Monitoring orders moved to Q3; the equipment order book is at a record level and Jakobs expects order growth to return to mid-single digits in Q3 and beyond.
- Regional view: North America strong (double-digit order growth over 12 months, HealthTrust 2026 Capital Supplier of the Year), Europe double-digit order growth (Poland, Karolinska, UK, Germany), China weak in health systems as centralised procurement expands; India is "really picking up a double-digit contribution".
- Diagnosis & Treatment margin excluding the refund fell to 9.3% on cost inflation, tariffs, currency and China; Image Guided Therapy grew for the 22nd consecutive quarter.
- Personal Health +8.5% comparable; new Sonicare ranges took back US market leadership in power toothbrushes; distribution gains at Walmart, Costco and pharmacies.
- Enterprise Informatics sales declined mid-single-digit while customers move to cloud; orders take 12 to 18 months to turn into revenue; the electronic medical records business was divested in Q2.
- Productivity EUR 258 million year-to-date; AI used internally (Illuminate makes concept development 50% faster, NOVA cuts requirements drafting time by around one-third).
- Full-year outlook: underlying Adjusted EBITA margin 12.5%-13%, Q3 margin below prior year, strong Q4 step-up; net debt EUR 5.7 billion, leverage 1.8x.
- Philips Capital Markets Day 2026 transcript
- Capital Markets Day (February 10, 2026): CEO Roy Jakobs says Philips has "stabilised the company" and enters "a next phase" focused on profitable growth; targets mid-single-digit sales CAGR, mid-teens Adjusted EBITA margin in 2028 and EUR 4.5-5 billion cumulative free cash flow over 2026-2028.
- Strategy in three pillars: focused value creation by segment (disproportionate investment in Monitoring and Interventional), innovation through data, AI and platforms, and disciplined execution with a step-up in commercial excellence.
- Platform advantage: installed base of more than 2.5 million systems, reaching 80% of top hospitals globally; partnerships with AWS (cloud diagnostics), Nvidia (foundation AI model for MRI), Mayo Clinic (cardiac MRI exam time from 60 to 20 minutes).
- Addressable market of EUR 90-100 billion growing 3%-5% a year; WHO-estimated shortfall of more than 10 million health workers by 2030 drives demand for productivity.
- CFO Charlotte Hanneman: EUR 2.5 billion productivity delivered 2023-2025, a new EUR 1.5 billion programme, R&D at around 9% of sales ("fewer, bigger and better"), adjusting items to fall from around 200 basis points in 2026 to industry levels; leverage down from 3 times in 2022 to 1.7 times in 2025.
- Segment targets to 2028: Image Guided Therapy (EUR 3.5 billion revenue, about 45% global share) mid-to-high-single-digit growth and margin above 20%; Precision Diagnosis (EUR 5 billion) low-to-mid-single-digit growth, low-teens margin; Connected Care mid-teens margin; Personal Health (EUR 3.7 billion, 18% margin) mid-single-digit growth and high-teens margin.
- New platforms: Azurion Eye AI cath-lab software, SpectraWAVE coronary imaging, helium-free 3T MR, Verida AI spectral CT, a next-generation monitoring care intelligence platform.
- US sleep therapy re-entry is excluded from the plan ("the timing of this return is not in our control"); China treated cautiously; North America is the core growth engine (double-digit growth every quarter of 2025).
Questions about Philips
What does Philips do?
Philips is a health technology company selling imaging, image-guided therapy, patient monitoring and informatics to hospitals, and personal health products such as Sonicare toothbrushes and shavers to consumers.
What is Philips' revenue?
FY2025 sales were EUR 17,834 million, up 2% comparable, with Adjusted EBITA of EUR 2,195 million. First-half 2026 sales were EUR 8,265 million.
How many people work at Philips?
About 65,000 employees, in 71 countries, according to the 2025 annual report.
What is Philips' strategy to 2028?
Mid-single-digit comparable sales growth, a mid-teens Adjusted EBITA margin in 2028, EUR 4.5-5.0 billion cumulative free cash flow and EUR 1.5 billion of productivity savings, with extra focus on Monitoring and Interventional and on AI-powered platforms.
Who leads Philips?
Roy Jakobs has been CEO since October 2022, with Charlotte Hanneman as CFO; the Supervisory Board is chaired by Feike Sijbesma.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)